Legend Biotech Corp, referenced on the NASDAQ exchange as LEGN, is a multinational biopharmaceutical company focused on discovering and developing innovative cell therapies for oncology and other illnesses. The company's impressive bioengineering technologies and clinical development expertise place it on the frontier of scientific discovery in the field of cell therapy and biological products for human therapeutic use.
Legend Biotech was originally established in 2014 as the subsidiary of GenScript Biotech Corporation, a global biotech company based in Nanjing, China. Since then, Legend Biotech has flourished, seeking to revolutionize medicine with technology designed to address unmet medical needs.
The company ploughs deep into the domain of CAR-T (Chimeric Antigen Receptor T-cell) therapies, which are treatments that use genetically modified cells from a patient's immune system to target and kill cancer cells. In collaboration with Johnson & Johnson’s Janssen unit, Legend Biotech has made significant progress in the development of its CAR-T cell therapy, particularly in the treatment of multiple myeloma, a blood cancer.
One of the firm's primary candidates is Cilta-cel, a CAR-T cell therapy co-developed with Janssen Biotech for treating relapsed or refractory multiple myeloma. The drug has so far demonstrated promising responses in clinical trials and is proceeding in pre-established strides toward regulatory approval.
Legend Biotech takes pride in fostering a dynamic, diverse, and inclusive culture that values every team member's input and perspective. The company is headquartered in Somerset, New Jersey, USA, with additional functions in California and in China.
The company commands a competitive status in the fast-evolving biotech industry. With their commitment to innovation and relentless pursuit of medical breakthroughs, Legend Biotech stands as a testament to continuous and dogged research in the field of biotechnology. They are geared towards providing effective and transformative solutions to patients by translating basic science into life-saving therapies.
Despite their relatively recent entrance into the market, the strides made by Legend Biotech Corp highlight their potential, strength, and capacity in a highly competitive industry. The company's unwavering dedication to researching and developing novel cell therapies has positioned it as a significant player on the stage of biotechnology and healthcare.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Legend Biotech Corp (NASDAQ: LEGN) released positive five-year follow-up data for its CAR T-cell therapy, Carvykti, for multiple myeloma, which supports its commercial prospects despite ongoing unprofitability. While the company's Price-to-Sales ratio is low compared to historical figures, suggesting undervaluation, its GF Score™ of 76/100 reflects strong growth and financial health but weak profitability. Insider selling and cautious guru activity suggest investors should carefully assess the risks alongside growth potential.
Legend Biotech Corp CFO Carlos E. Santos acquired 19,676 ordinary shares at no cost and simultaneously sold 5,430 ordinary shares at a weighted average price of $9.14 per share on September 21, 2026. The sale was primarily conducted to cover withholding tax obligations related to the vesting of restricted share units. Following these transactions, Santos directly holds 14,246 ordinary shares in the company.
Legend Biotech has appointed Ingrid Zhang as its new Chief Executive Officer, effective September 15, 2026. Zhang, an accomplished global biopharmaceutical executive with previous leadership roles at Novartis, AstraZeneca, Pfizer, and McKinsey & Company, succeeds Alan Bash who served as Interim CEO. The Board believes Zhang's strategic vision and operational discipline will guide the company through its next phase of growth in cell therapy.
_07_03_2026_03_50_21_133108.jpg)
Legend Biotech Corp CEO Ingrid Zhang was granted 1,131,860 restricted share units (RSUs) on September 15, 2026, at a price of $0. These RSUs will vest in three annual installments starting September 15, 2027, contingent on her continued employment. This transaction was disclosed in a Form 4 filed on September 16, 2026, and increases her direct ownership to 1,131,860 ordinary shares.